Skip to main content
Erschienen in: PharmacoEconomics 2/2014

01.02.2014 | Practical Application

Survival Modeling for the Estimation of Transition Probabilities in Model-Based Economic Evaluations in the Absence of Individual Patient Data: A Tutorial

verfasst von: Vakaramoko Diaby, Georges Adunlin, Alberto J. Montero

Erschienen in: PharmacoEconomics | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

Survival modeling techniques are increasingly being used as part of decision modeling for health economic evaluations. As many models are available, it is imperative for interested readers to know about the steps in selecting and using the most suitable ones. The objective of this paper is to propose a tutorial for the application of appropriate survival modeling techniques to estimate transition probabilities, for use in model-based economic evaluations, in the absence of individual patient data (IPD). An illustration of the use of the tutorial is provided based on the final progression-free survival (PFS) analysis of the BOLERO-2 trial in metastatic breast cancer (mBC).

Methods

An algorithm was adopted from Guyot and colleagues, and was then run in the statistical package R to reconstruct IPD, based on the final PFS analysis of the BOLERO-2 trial. It should be emphasized that the reconstructed IPD represent an approximation of the original data. Afterwards, we fitted parametric models to the reconstructed IPD in the statistical package Stata. Both statistical and graphical tests were conducted to verify the relative and absolute validity of the findings. Finally, the equations for transition probabilities were derived using the general equation for transition probabilities used in model-based economic evaluations, and the parameters were estimated from fitted distributions.

Results

The results of the application of the tutorial suggest that the log-logistic model best fits the reconstructed data from the latest published Kaplan–Meier (KM) curves of the BOLERO-2 trial. Results from the regression analyses were confirmed graphically. An equation for transition probabilities was obtained for each arm of the BOLERO-2 trial.

Conclusions

In this paper, a tutorial was proposed and used to estimate the transition probabilities for model-based economic evaluation, based on the results of the final PFS analysis of the BOLERO-2 trial in mBC. The results of our study can serve as a basis for any model (Markov) that needs the parameterization of transition probabilities, and only has summary KM plots available.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Briggs AH, Claxton K, Sculpher MJ. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006. Briggs AH, Claxton K, Sculpher MJ. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006.
2.
Zurück zum Zitat Goeree R, Diaby V. Introduction to health economics and decision-making: is economics relevant for the frontline clinician? Best Pract Res Clin Gastroenterol. 2013;27(6):831–44.PubMedCrossRef Goeree R, Diaby V. Introduction to health economics and decision-making: is economics relevant for the frontline clinician? Best Pract Res Clin Gastroenterol. 2013;27(6):831–44.PubMedCrossRef
3.
Zurück zum Zitat Latimer NR. Survival analysis for economic evaluations alongside clinical trials—extrapolation with patient-level data: inconsistencies, limitations, and a practical guide. Med Decis Making. 2013;33(6):743–54.PubMedCrossRef Latimer NR. Survival analysis for economic evaluations alongside clinical trials—extrapolation with patient-level data: inconsistencies, limitations, and a practical guide. Med Decis Making. 2013;33(6):743–54.PubMedCrossRef
5.
Zurück zum Zitat Stevenson M, Street R, Jones ML, Kearns B, Street S, Littlewood C, et al. Cabazitaxel for the second-line treatment of hormone refractory, metastatic prostate cancer: a single technology appraisal. ScHARR: The University of Sheffield; 2011. Stevenson M, Street R, Jones ML, Kearns B, Street S, Littlewood C, et al. Cabazitaxel for the second-line treatment of hormone refractory, metastatic prostate cancer: a single technology appraisal. ScHARR: The University of Sheffield; 2011.
6.
Zurück zum Zitat Ghosh K, Tiwari RC. Nonparametric and semiparametric Bayesian reliability analysis. In: Ruggeri F, Kenett R, Faltin FW, editors. Encyclopedia of statistics in quality and reliability. Chichester, UK: Wiley; 2007. p. 1239–1248. Ghosh K, Tiwari RC. Nonparametric and semiparametric Bayesian reliability analysis. In: Ruggeri F, Kenett R, Faltin FW, editors. Encyclopedia of statistics in quality and reliability. Chichester, UK: Wiley; 2007. p. 1239–1248.
7.
Zurück zum Zitat Coon JT, Hoyle M, Green C, Liu Z, Welch K, Moxham T, et al. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. Health Technol Assess. 2010;14:1–208. Coon JT, Hoyle M, Green C, Liu Z, Welch K, Moxham T, et al. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. Health Technol Assess. 2010;14:1–208.
8.
Zurück zum Zitat Rogers G, Hoyle M, Coon JT, Moxham T, Liu Z, Pitt M, et al. Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation. Health Technol Assess. 2012;16(22):1–410. doi:10.3310/hta16220. Rogers G, Hoyle M, Coon JT, Moxham T, Liu Z, Pitt M, et al. Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation. Health Technol Assess. 2012;16(22):1–410. doi:10.​3310/​hta16220.
9.
Zurück zum Zitat Guyot P, Ades AE, Ouwens MJNM, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan–Meier survival curves. BMC Med Res Methodol. 2012;12:9.PubMedCentralPubMedCrossRef Guyot P, Ades AE, Ouwens MJNM, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan–Meier survival curves. BMC Med Res Methodol. 2012;12:9.PubMedCentralPubMedCrossRef
10.
Zurück zum Zitat Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520–9. Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520–9.
12.
Zurück zum Zitat Akaike H. A new look at the statistical model identification. IEEE Trans Autom Contr. 1974;19(6):716–23.CrossRef Akaike H. A new look at the statistical model identification. IEEE Trans Autom Contr. 1974;19(6):716–23.CrossRef
13.
Zurück zum Zitat Schwarz G. Estimating the dimension of a model. Ann Stat. 1978;6(2):461–4.CrossRef Schwarz G. Estimating the dimension of a model. Ann Stat. 1978;6(2):461–4.CrossRef
14.
Zurück zum Zitat Moeschberger ML, Klein JP. Survival analysis: techniques for censored and truncated data. Berlin: Springer; 2003. Moeschberger ML, Klein JP. Survival analysis: techniques for censored and truncated data. Berlin: Springer; 2003.
15.
Zurück zum Zitat Royston P, Lambert PC. Flexible parametric survival analysis using stata: beyond the Cox model. College Station: Stata Press; 2011. Royston P, Lambert PC. Flexible parametric survival analysis using stata: beyond the Cox model. College Station: Stata Press; 2011.
16.
Zurück zum Zitat Jackson CH, Sharples LD, Thompson SG. Survival models in health economic evaluations: balancing fit and parsimony to improve prediction. Int J Biostat. 2010;6(1):34.CrossRef Jackson CH, Sharples LD, Thompson SG. Survival models in health economic evaluations: balancing fit and parsimony to improve prediction. Int J Biostat. 2010;6(1):34.CrossRef
Metadaten
Titel
Survival Modeling for the Estimation of Transition Probabilities in Model-Based Economic Evaluations in the Absence of Individual Patient Data: A Tutorial
verfasst von
Vakaramoko Diaby
Georges Adunlin
Alberto J. Montero
Publikationsdatum
01.02.2014
Verlag
Springer International Publishing
Erschienen in
PharmacoEconomics / Ausgabe 2/2014
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI
https://doi.org/10.1007/s40273-013-0123-9

Weitere Artikel der Ausgabe 2/2014

PharmacoEconomics 2/2014 Zur Ausgabe